Angiotensin-converting enzyme inhibitors in the treatment of hypertension;Empleo de los inhibidores de la enzima convertidora de la angiotensina en el tratamiento de la hipertensión arterial

Revista Argentina de Cardiologia

Volumn 79, Issue 2, 2011, Pages 103-105

  de Dios, Ana María ^a,b  

^a HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^b SOCIEDAD ARGENTINA DE CARDIOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FIRST TRIMESTER PREGNANCY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; PRENATAL DRUG EXPOSURE; PRIMARY PREVENTION; TERATOGENICITY;

EID: 80052682951     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Macmahon S, Alderman MH, Lindholm LH, Liu L, Sanchez RA, Seedat YK. Blood pressure-related disease is a global health priority. Lancet 2008;371:1480-2.
2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
3. Grupo de Hipertensión. Consenso sobre factores de riesgo de enfermedad cardiovascular en pediatría. Hipertensión arterial en el niño y el adolescente. Arch Argent Pediatr 2005;103:348-66.
4. Bendersky M. Asociaciones de drogas en hipertensión arterial. Rev Fed Arg Cardiol 2010;39:16-21.
5. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6.
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectation from prospective epidemiological studies. BMJ 2009;338:b1665.
7. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354(23):2443-51.
8. Bernztein RG, Drake I. Prescripción de enalapril a la mujer fértil como factor de riesgo de malformaciones congénitas en el primer nivel de atención pública de la Argentina. Rev Argent Cardiol 2011;79:111-6.
9. Colvin L, Slack-Smith L, Stanley F, Bower C. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010;19:1137-50.
10. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol 2009;113:166-88.
11. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-37.
12. MIMS Australia Pty Ltd. Monthly Index of Medical Specialties Online. 2009 [cited 11 June 2009]